Upstream Bio, Inc. (NASDAQ:UPB) Stock Rated “Hold” by Sell-Side Brokerages

Upstream Bio, Inc. (NASDAQ:UPB) has earned an average rating of “Hold” from the seven analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $29.67.

A number of brokerages recently weighed in on UPB. Weiss Ratings upgraded shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Wall Street Zen lowered shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Truist Financial lowered their target price on shares of Upstream Bio to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of Upstream Bio in a research report on Wednesday, September 2nd. Finally, JPMorgan Chase & Co. boosted their target price on Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, August 14th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of UPB. BlackRock Inc. acquired a new stake in Upstream Bio in the 2nd quarter valued at about $25,973,000. SEB Asset Management AB bought a new position in shares of Upstream Bio during the 1st quarter valued at about $7,906,000. Parkman Healthcare Partners LLC acquired a new position in shares of Upstream Bio in the 2nd quarter worth approximately $6,472,000. Hsbc Holdings PLC acquired a new position in shares of Upstream Bio in the 1st quarter worth approximately $5,763,000. Finally, Walleye Capital LLC acquired a new position in shares of Upstream Bio in the 2nd quarter worth approximately $3,450,000.

Upstream Bio Price Performance

Shares of UPB stock opened at $3.23 on Friday. Upstream Bio has a 12-month low of $2.68 and a 12-month high of $33.68. The firm has a market capitalization of $176.91 million, a price-to-earnings ratio of -1.11 and a beta of 1.60. The business has a 50 day simple moving average of $4.57 and a 200 day simple moving average of $8.80.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%. The company had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.56 million. On average, equities analysts anticipate that Upstream Bio will post -2.84 EPS for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company’s research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues.

Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses.